Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases

References

• Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Gonçalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32:4655–11.
   PubMed Web of Science ®Google Scholar
• Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78–84. doi:10.1016/j.lungcan.2014.07.020.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–1833. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic non–small-Cell lung cancer. N Engl J Med. 2018;378:2078–2092. doi:10.1056/NEJMoa1801005.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655–663. doi:10.1016/S1470-2045(20)30111-X.
   PubMed Web of Science ®Google Scholar
• Hou X, Zhou C, Wu G, Lin W, Xie Z, Zhang H, Yi J, Peng Z, Yin L, Ma C, et al. Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous NSCLC with brain metastases (CAP-BRAIN): a multicenter, open-label, single-arm, phase 2 study. J Thorac Oncol. 2023;18(6):769–779. doi:10.1016/j.jtho.2023.01.083.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi:10.1056/NEJMoa1113205.
   PubMed Web of Science ®Google Scholar
• Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, et al. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol. 2019;30(9):1521–1530. doi:10.1093/annonc/mdz207.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016;27:1953–8. doi:10.1093/annonc/mdw289.
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. doi:10.1038/ncomms9839.
   PubMed Web of Science ®Google Scholar
• Li M, Chen J, Zhang B, Yu J, Wang N, Li D, Shao Y, Zhu D, Liang C, Ma Y, et al. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028). BMC Med. 2022;20(1):398.
   PubMed Web of Science ®Google Scholar
• Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, et al. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nat Commun. 2021;12(1):1503. doi:10.1038/s41467-021-21789-x.
   PubMed Web of Science ®Google Scholar
• Assarsson E, Lundberg M, Holmquist G, Björkesten J, Bucht Thorsen S, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4):e95192. doi:10.1371/journal.pone.0095192.
   PubMed Web of Science ®Google Scholar
• De Marchi P, Leal LF, da Silva V D, da Silva ECA, Cordeiro de Lima VC, Reis RM. PD-L1 expression by tumor proportion score (TPS) and combined positive score (CPS) are similar in non-small cell lung cancer (NSCLC). J Clin Pathol. 2021;74:735–740. doi:10.1136/jclinpath-2020-206832.
   PubMed Web of Science ®Google Scholar
• Ulas EB, Hashemi SMS, Houda I, Kaynak A, Veltman JD, Fransen MF, Radonic T, Bahce I. Predictive value of combined positive score and tumor proportion score for immunotherapy response in advanced NSCLC. JTO Clin Res Rep. 2023;4:100532. doi:10.1016/j.jtocrr.2023.100532.
   PubMedGoogle Scholar
• Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18(2):123–131. doi:10.1038/ni.3666.
   PubMed Web of Science ®Google Scholar
• Li M, Hou X, Sai K, Wu L, Chen J, Zhang B, Wang N, Wu L, Zheng H, Zhang J, et al. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060). Oncoimmunology. 2022;11(1):2059874. doi:10.1080/2162402X.2022.2059874.
   PubMed Web of Science ®Google Scholar
• Lok E, Chung AS, Swanson KD, Wong ET. Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. Melanoma Res. 2014;24:120–30. doi:10.1097/CMR.0000000000000045.
   PubMed Web of Science ®Google Scholar
• Lee YB, Nagai A, Kim SU. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res. 2002;69(1):94–103. doi:10.1002/jnr.10253.
   PubMed Web of Science ®Google Scholar
• Wang M, Xie Z, Xu J, Feng Z. TWEAK/Fn14 axis in respiratory diseases. Clin Chim Acta. 2020;509:139–148. doi:10.1016/j.cca.2020.06.007.
   PubMed Web of Science ®Google Scholar
• Ma J, Huang L, Gao YB, Li M-X, Chen L-L, Yang L. M2 macrophage facilitated angiogenesis in cutaneous squamous cell carcinoma via circ_TNFRSF21/miR-3619-5p/ROCK axis. Kaohsiung J Med Sci. 2022;38:761–771. doi:10.1002/kjm2.12555.
   PubMed Web of Science ®Google Scholar
• Zaitseva O, Hoffmann A, Otto C, Wajant, H. Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy. Front Pharmacol. 2022;13:935086. doi:10.3389/fphar.2022.935086.
   PubMed Web of Science ®Google Scholar
• Iwata R, Hyoung Lee J, Hayashi M, Dianzani U, Ofune K, Maruyama M, Oe S, Ito T, Hashiba T, Yoshimura K, et al. ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma. Neuro Oncol. 2020;22:333–344. doi:10.1093/neuonc/noz204.
   PubMed Web of Science ®Google Scholar
• Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, Anderson S, Atkinson N, Ramirez PT, Liu Y-J, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res. 2012;72:5240–9. doi:10.1158/0008-5472.CAN-12-2271.
   PubMed Web of Science ®Google Scholar
• Powell SF, Rodríguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp H-G, Rodríguez-Cid J, Kowalski DM, Cheng Y, Kurata T, et al. Outcomes with Pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 2021;16(11):1883–1892. doi:10.1016/j.jtho.2021.06.020.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for Previously untreated metastatic nonsquamous non–small-Cell lung cancer. J Clin Oncol. 2020;38:1505–1517. doi:10.1200/JCO.19.03136.
   PubMed Web of Science ®Google Scholar
• Alessandrini F, Pezzè L, Ciribilli Y. Lamps: shedding light on cancer biology. Semin Oncol. 2017;44(4):239–253. doi:10.1053/j.seminoncol.2017.10.013.
   PubMed Web of Science ®Google Scholar
• Liu Y, He S, Wang XL, Peng W, Chen Q-Y, Chi D-M, Chen J-R, Han B-W, Lin G-W, Li Y-Q, et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. Nat Commun. 2021;12(1):741. doi:10.1038/s41467-021-21043-4.
   PubMed Web of Science ®Google Scholar
• Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, Qin S, Zhang L, Ouyang H, Du P, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184(3):792–809.e23. doi:10.1016/j.cell.2021.01.010.
   PubMed Web of Science ®Google Scholar
• Rodrigues G, Hoshino A, Kenific CM, Matei IR, Steiner L, Freitas D, Kim HS, Oxley PR, Scandariato I, Casanova-Salas I, et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019;21(11):1403–1412. doi:10.1038/s41556-019-0404-4.
   PubMed Web of Science ®Google Scholar
• Fares J, Cordero A, Kanojia D, Lesniak MS. The network of cytokines in brain metastases. Cancers Basel. 2021;13:2021. doi:10.3390/cancers13010142.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Schreck KC, Fu W, Hu C, Carvajal-Gonzalez A, Connolly RM, Santa-Maria CA, Lipson EJ, Holdhoff M, Forde PM, et al. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J Immunother Cancer. 2021;9(8):e002473.
   Web of Science ®Google Scholar
• Yang R, Hung MC. The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. Sci China Life Sci. 2017;60(10):1058–1064. doi:10.1007/s11427-017-9176-7.
   PubMed Web of Science ®Google Scholar
• Lv Y, Ma X, Ma Y, Du Y, Feng J. A new emerging target in cancer immunotherapy: galectin-9 (LGALS9). Genes Dis. 2023;10:2366–2382. doi:10.1016/j.gendis.2022.05.020.
   PubMed Web of Science ®Google Scholar
• Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, Niki T, Tominaga A, Yamauchi A, Hirashima M, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology. 2008;18(9):735–744. doi:10.1093/glycob/cwn062.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Arikawa T, Shinonaga R, Oomizu S, Inagawa H, Soma G, Niki T, Hirashima M. Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages. Clin Immunol. 2012;142:296–307. doi:10.1016/j.clim.2011.11.006.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Ciuleanu TE, Lee JS, Pluzanski A, Caro RB, Gutierrez M, Ohe Y, Nishio M, Goldman J, Ready N, et al. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. Ann Oncol. 2023;34(2):173–185. doi:10.1016/j.annonc.2022.11.006.
   PubMed Web of Science ®Google Scholar
• von Pawel J, Bordoni R, Satouchi M, von Pawel J, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, et al. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: results from the randomised phase III OAK study. Eur J Cancer. 2019;107:124–132. doi:10.1016/j.ejca.2018.11.020.
   PubMed Web of Science ®Google Scholar
• Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez‐Marti A, Pardo N, Saoudi‐Gonzalez N, Martinez D, et al. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol. 2021;15(4):887–900. doi:10.1002/1878-0261.12891.
   PubMed Web of Science ®Google Scholar
• Herradon G, Ramos-Alvarez MP, Gramage E. Gramage E: connecting metainflammation and neuroinflammation through the PTN-MK-RPTPβ/ζ axis: relevance in therapeutic development. Front Pharmacol. 2019;10:377. doi:10.3389/fphar.2019.00377.
   PubMed Web of Science ®Google Scholar
• Shi Y, Ping YF, Zhou W, He Z-C, Chen C, Bian BSJ, Zhang L, Chen L, Lan X, Zhang X-C, et al. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017;8(1):15080. doi:10.1038/ncomms15080.
   PubMedGoogle Scholar
• Sun R, Gao DS, Shoush J, Lu, B. The IL-1 family in tumorigenesis and antitumor immunity. Semin Cancer Biol. 2022;86:280–295. doi:10.1016/j.semcancer.2022.05.002.
   PubMed Web of Science ®Google Scholar
• Inoue N, Li W, Fujimoto Y, MatsushitA Y, Katagiri T, Okamura H, Miyoshi Y. High serum levels of Interleukin-18 are associated with worse outcomes in patients with breast cancer. Anticancer Res. 2019;39:5009–5018. doi:10.21873/anticanres.13691.
   PubMed Web of Science ®Google Scholar
• El-Deeb MMK, El-Sheredy HG, Mohammed AF. The possible role of Interleukin (IL)-18 and Nitrous Oxide and their relation to oxidative stress in the development and progression of breast cancer. Asian Pac J Cancer Prev. 2019;20(9):2659–2665. doi:10.31557/APJCP.2019.20.9.2659.
   PubMedGoogle Scholar
• Kang JS, Bae SY, Kim HR, Kim YS, Kim DJ, Cho BJ, Yang H-K, Hwang Y-I, Kim KJ, Park HS, et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis. 2009;30(12):1987–1996. doi:10.1093/carcin/bgp158.
   PubMed Web of Science ®Google Scholar
• Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M, Ascierto PA, Ciliberto G, Arra C. Interleukin 18: friend or foe in cancer. Biochim Biophys Acta. 2013;1836:296–303. doi:10.1016/j.bbcan.2013.09.001.
   PubMed Web of Science ®Google Scholar
• Baker KJ, Houston A, Brint E. IL-1 family members in cancer; two sides to every story. Front Immunol. 2019;10:1197. doi:10.3389/fimmu.2019.01197.
   PubMed Web of Science ®Google Scholar
• Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol. 2015;97(4):665–675. doi:10.1189/jlb.5RU0714-360RR.
   PubMed Web of Science ®Google Scholar